Recently, the "Clinical study of chimeric Antigen Receptor Macrophages (CAR-M) in the treatment of relapsed and refractory ovarian Cancer" project submitted by Kunshi Biotechnology Co., Ltd. passed the ethical review of the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University, obtained the ethical approval, and was approved to carry out investigator-initiated clinical trials (IIT). The approval of the project marks the formal entry of the CAR-M pipeline of Kunshi Biology into the clinical research stage. Kunshi Biology has been committed to the original innovation and clinical transformation of CAR-M cell therapy, relying on its safe and mature technology platform to develop cell drugs for solid tumors such as ovarian cancer and brain glioma. The Affiliated Hospital of Xuzhou Medical University, which cooperates with Kunshi Biology, has rich clinical experience and technical accumulation in immune cell therapy research. Kunshi Bioscience also sincerely thanks the clinical trial service organization Jiangsu Jizui Bioscience Research Institute Co., Ltd. for its organization and coordination in the process of promoting the ethical review of clinical research projects.

About RocRock creatures

RocRock Biotechnology Co., Ltd. was incubated in Berlin, Germany, and established in Shenzhen, China in April 2021. At present, it has completed the three-body layout of the domestic Shenzhen Information center, the Suzhou production center and the Berlin international center. Kunshi Biology is led by returned Chinese scientists from Europe, and from the field of life sciences Karolinska Institutet, the European Molecular Biology Laboratory, the German National Center for Molecular Medicine and many other scientific research institutions and pharmaceutical companies, the joint doctor, relying on the scientific research team of more than 10 years of cutting-edge scientific research results, the establishment of biomedical strategic high-tech enterprises. Kunshi Biology, focusing on the immune cell therapy of macrophages, actively promotes the research and development and industrialization of high-tech technology of chimeric antigen receptor of macrophages CAR-M, and creates a global leading closed-loop industrial chain, making Chinese local enterprises in the forefront of the world in the field of macrophage treatment of solid tumors.

About Xuzhou Medical University Affiliated Hospital

The Affiliated Hospital of Xuzhou Medical University has a national Phase I clinical research center. The clinical trial Ethics Committee of the hospital passed the SIDCER-FERCAP international ethics certification in 2015, and its ethical review technology and management level ranks among the advanced ranks in China. It is the only ethics committee in Huaihai Economic Zone that has passed the FERCAP certification. At present, more than 50 clinical trials of CAR-T immune cell therapy have been carried out, and it is one of the hospitals that carry out the most CAR-T clinical trials in China.

About the collection of emergent creatures

Jiangsu Jucui JuChuang Biotechnology Research Institute Co., Ltd., relying on Xuzhou Medical University and Jiangsu Institute of Cancer Biotherapy, is the only cell therapy drug research institute established by the Yangtze River Delta National Innovation Center for the one city and three provinces. It is committed to building a first-class domestic platform for cancer biotherapy technology that integrates research and development, transformation, and clinical application. With over 20 years of basic research and industrial exploration experience in the field of cell therapy, it has a relatively mature R&D and clinical translation team system. It has independently developed multiple full-human source CAR-T product pipelines and carried out a number of IIT clinical studies.